Cargando…

Use of intravenous tocilizumab in pregnancy for severe coronavirus disease 2019 pneumonia: two case reports

BACKGROUND: Tocilizumab, an interleukin-6 inhibitor is part of many international guidelines for the management of cytokine storm associated with severe coronavirus disease 2019 with observed improvements. However, this drug is not recommended during pregnancy owing to the lack of safety data. Restr...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdullah, Shazia, Bashir, Nihal, Mahmood, Nageena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8346777/
https://www.ncbi.nlm.nih.gov/pubmed/34364393
http://dx.doi.org/10.1186/s13256-021-03010-1
_version_ 1783734948379754496
author Abdullah, Shazia
Bashir, Nihal
Mahmood, Nageena
author_facet Abdullah, Shazia
Bashir, Nihal
Mahmood, Nageena
author_sort Abdullah, Shazia
collection PubMed
description BACKGROUND: Tocilizumab, an interleukin-6 inhibitor is part of many international guidelines for the management of cytokine storm associated with severe coronavirus disease 2019 with observed improvements. However, this drug is not recommended during pregnancy owing to the lack of safety data. Restriction of such medication use makes the management of coronavirus disease 2019 in pregnant women more challenging. Pregnant women are more likely to deteriorate from respiratory infections because of the immunological changes during pregnancy and the hypoxic compromise. We report the use of tocilizumab in two pregnant patients who developed severe coronavirus disease 2019 with a successful outcome. To date, there have not been any published data on tocilizumab use in pregnancy for cytokine storm syndrome associated with coronavirus disease 2019. CASE PRESENTATIONS: In 2020, two pregnant women of Asian origin in the last trimester of pregnancy were admitted to our hospital with severe coronavirus disease 2019. Their clinical condition progressed rapidly despite maximum supportive treatments. Blood testing in the second week of illness showed rising ferritin and interleukin-6 levels, indicating the possibility of cytokine storm syndrome. Both developed respiratory failure necessitating mechanical ventilation. Due to their critical clinical condition and lack of response to supportive treatment, a decision was made to use intravenous tocilizumab therapy. Both were treated with one intravenous infusion of tocilizumab and had a successful outcome. They were extubated later and gradually weaned off supplemental oxygen. The first patient continued with her pregnancy during the hospital stay with normal fetal scans. The second patient needed an emergency cesarean section and delivered a healthy infant. CONCLUSION: In critical clinical situations, tocilizumab may have a role in managing coronavirus disease 2019 related cytokine storm during pregnancy.
format Online
Article
Text
id pubmed-8346777
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-83467772021-08-09 Use of intravenous tocilizumab in pregnancy for severe coronavirus disease 2019 pneumonia: two case reports Abdullah, Shazia Bashir, Nihal Mahmood, Nageena J Med Case Rep Case Report BACKGROUND: Tocilizumab, an interleukin-6 inhibitor is part of many international guidelines for the management of cytokine storm associated with severe coronavirus disease 2019 with observed improvements. However, this drug is not recommended during pregnancy owing to the lack of safety data. Restriction of such medication use makes the management of coronavirus disease 2019 in pregnant women more challenging. Pregnant women are more likely to deteriorate from respiratory infections because of the immunological changes during pregnancy and the hypoxic compromise. We report the use of tocilizumab in two pregnant patients who developed severe coronavirus disease 2019 with a successful outcome. To date, there have not been any published data on tocilizumab use in pregnancy for cytokine storm syndrome associated with coronavirus disease 2019. CASE PRESENTATIONS: In 2020, two pregnant women of Asian origin in the last trimester of pregnancy were admitted to our hospital with severe coronavirus disease 2019. Their clinical condition progressed rapidly despite maximum supportive treatments. Blood testing in the second week of illness showed rising ferritin and interleukin-6 levels, indicating the possibility of cytokine storm syndrome. Both developed respiratory failure necessitating mechanical ventilation. Due to their critical clinical condition and lack of response to supportive treatment, a decision was made to use intravenous tocilizumab therapy. Both were treated with one intravenous infusion of tocilizumab and had a successful outcome. They were extubated later and gradually weaned off supplemental oxygen. The first patient continued with her pregnancy during the hospital stay with normal fetal scans. The second patient needed an emergency cesarean section and delivered a healthy infant. CONCLUSION: In critical clinical situations, tocilizumab may have a role in managing coronavirus disease 2019 related cytokine storm during pregnancy. BioMed Central 2021-08-07 /pmc/articles/PMC8346777/ /pubmed/34364393 http://dx.doi.org/10.1186/s13256-021-03010-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Abdullah, Shazia
Bashir, Nihal
Mahmood, Nageena
Use of intravenous tocilizumab in pregnancy for severe coronavirus disease 2019 pneumonia: two case reports
title Use of intravenous tocilizumab in pregnancy for severe coronavirus disease 2019 pneumonia: two case reports
title_full Use of intravenous tocilizumab in pregnancy for severe coronavirus disease 2019 pneumonia: two case reports
title_fullStr Use of intravenous tocilizumab in pregnancy for severe coronavirus disease 2019 pneumonia: two case reports
title_full_unstemmed Use of intravenous tocilizumab in pregnancy for severe coronavirus disease 2019 pneumonia: two case reports
title_short Use of intravenous tocilizumab in pregnancy for severe coronavirus disease 2019 pneumonia: two case reports
title_sort use of intravenous tocilizumab in pregnancy for severe coronavirus disease 2019 pneumonia: two case reports
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8346777/
https://www.ncbi.nlm.nih.gov/pubmed/34364393
http://dx.doi.org/10.1186/s13256-021-03010-1
work_keys_str_mv AT abdullahshazia useofintravenoustocilizumabinpregnancyforseverecoronavirusdisease2019pneumoniatwocasereports
AT bashirnihal useofintravenoustocilizumabinpregnancyforseverecoronavirusdisease2019pneumoniatwocasereports
AT mahmoodnageena useofintravenoustocilizumabinpregnancyforseverecoronavirusdisease2019pneumoniatwocasereports